Clinical trials
ER Positive Breast Cancer clinical trials
Below are recruiting er positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 437 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07631052RecruitingPhase 2
Low-dose Capecitabine for High-risk Early Breast Cancer
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Toronto, OntarioAges 18 years+ - NCT07647016RecruitingPhase 2
New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT06650748Enrolling by invitationPhase 2
A study of hormone therapy with or without a targeted drug for breast cancer
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
BeijingAges 18–70 - NCT06966700RecruitingPhase 3
Study of Sac-TMT in Early High-Risk Breast Cancer
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT07427394RecruitingPhase 2
Camizestrant and atirmociclib for advanced breast cancer
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
St Louis, MissouriAges 18 years+ - NCT07310420RecruitingPhase 1
Zoladex injection for ovarian suppression in advanced breast cancer
This trial tests a single injection of Zoladex (goserelin) to see how well it suppresses ovarian function in premenopausal women with HR+, HER2- advanced breast cancer. It may be an option if you are still having periods and your cancer has spread or cannot be removed by surgery.
Hot Springs, ArkansasAges 18–55 - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT04263298RecruitingPhase 3
Fulvestrant or capecitabine after chemo for metastatic breast cancer
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Guangzhou, GuangdongAges 18–75 - NCT04990921RecruitingPhase 2
Palliative radiation plus pembrolizumab for metastatic breast cancer
This trial studies whether adding a focused, comfort-focused form of radiation (SBRT) to pembrolizumab can help people with stage IV breast cancer that cannot be removed with surgery. You may be eligible if you can receive palliative SBRT and have measurable tumors, and if you meet prior-therapy and blood/health criteria.
Louisville, KentuckyAges 18 years+ - NCT05528133RecruitingPhase 2
Personalized radiation based on tumor genetics in triple-negative breast cancer
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
Clearwater, FloridaAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05753657RecruitingEarly Phase 1
Testing insulin and blood sugar monitoring with pioglitazone
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
HaifaAges 18–85 - NCT06107673RecruitingPhase 2
Pill vs chemo before breast cancer surgery
This study compares taking a daily pill (dalpiciclib with hormone therapy) versus standard chemotherapy before breast cancer surgery. It's for postmenopausal women with a common type of early breast cancer that is strongly hormone-receptor positive and HER2-negative.
Shijiazhuang, HebeiAges 18–75 - NCT06615466Recruiting
Short radiation course for early stage breast cancer
This trial tests a shorter, more intense radiation schedule for women with early stage breast cancer after lumpectomy. It aims to provide effective treatment with fewer visits, which may be more convenient for patients.
Beijing, Beijing MunicipalityAges 45–74 - NCT07151911Recruiting
Study of drugs for high-risk early breast cancer
This study looks at the effectiveness of the drugs abemaciclib and olaparib plus hormone therapy for people with high-risk, hormone receptor-positive, HER2-negative early breast cancer. It aims to understand how well these treatments work in real-world settings.
Modena, ModenaAges 18 years+ - NCT07383818RecruitingPhase 2
Neoadjuvant therapy with trastuzumab rezetecan and toripalimab for HR+/HER2-low breast cancer
This trial tests a combination of two drugs (trastuzumab rezetecan and toripalimab) given before surgery to treat a specific type of breast cancer that is hormone-receptor-positive and HER2-low. It aims to see if this treatment can improve outcomes for patients who have not had prior cancer treatment.
HarbinAges 18–70 - NCT07524855RecruitingPhase 1
HLD-0117 study for metastatic breast cancer
This early-stage study tests a new drug called HLD-0117 in women whose metastatic breast cancer (cancer that has spread beyond the breast) has stopped responding to previous hormone and targeted therapies. The goal is to see if this drug can slow or shrink the cancer in patients who have limited options left.
New Haven, ConnecticutAges 18 years+ - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
Birmingham, AlabamaAges 18 years+ - NCT05190094RecruitingPhase 2
Test blood-based laser scan to guide first-line breast cancer treatment
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
BlidaAges 18 years+ - NCT07078604RecruitingPhase 2
Vaccine with chemotherapy for advanced triple-negative breast cancer
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
Seattle, WashingtonAges 18 years+ - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT07400523RecruitingPhase 3
Ribociclib for breast cancer with leftover disease after chemo
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
Zhanjiang, GuangdongAges 18 years+
Hear when a new ER Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er positive breast cancer?
- Yes. Clin2 currently lists 437 recruiting er positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HER2-positive Breast Cancer
- Hormone-receptor-positive Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Node-positive Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.